Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.

Drug metabolism and pharmacokinetics - 1 Jan 2014

Stockis Armel, Watanabe Shikiko, Rouits Elisabeth, Matsuguma Kyoko, Irie Shin

Abstract excerpt

Brivaracetam is a high-affinity synaptic vesicle protein 2A ligand, in phase 3 clinical development for epilepsy. A phase 1, single-center, randomized, double-blind, placebo-controlled, single (2.5-100 mg) and multiple (2.5-50 mg twice daily) rising oral dose study (N01209) was conducted to assess the adverse event profile and pharmacokinetics of brivaracetam in healthy Japanese men, and the influence of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Double-Blind Method

Share to Healthy Volunteers

Share to Pyrrolidinones

Share to Young Adult

Source

Identifiers

PMID: 24717838
DOI: 10.2133/dmpk.dmpk-14-rg-010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.PMID 24717838Read ↗

Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.Semantic proximity Read ↗

ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics.Semantic proximity Read ↗

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.Semantic proximity Read ↗

A Multiscale Structural, Pharmacokinetic–Pharmacodynamic and Systems Pharmacology Framework Exploring a Plausible Interaction Between Cenobamate and Low-Dose Clobazam in Drug-Resistant EpilepsySemantic proximity Read ↗

The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discoverySemantic proximity Read ↗

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation studySemantic proximity Read ↗

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.Semantic proximity Read ↗

Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.Semantic proximity Read ↗

Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.Semantic proximity Read ↗

Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.